Juvena Therapeutics
Juvena Therapeutics is a computationally-driven biopharmaceutical company focused on discovering and developing novel biologic medicines derived from secreted proteins to restore tissue homeostasis and treat degenerative diseases such as myopathies and metabolic disorders. Utilizing an AI-enabled platform, Juvena mines a diverse library of proteins secreted by human stem cells, mapping their therapeutic potential through in silico, in vitro, and in vivo methods, and engineers these proteins into biologics that promote tissue repair and regeneration. Their lead asset, JUV-161, is in Phase 1 clinical trials for myotonic dystrophy type 1 and sarcopenia, with additional preclinical programs targeting obesity, lung, and liver diseases. Juvena has established significant collaborations, including with the Myotonic Dystrophy Foundation and Eli Lilly, and has been recognized as a World Economic Forum Technology Pioneer and featured in major biotech news outlets. The company operates from Redwood City, California, and is led by a team of experts in computational drug discovery, proteomics, pharmacology, and protein engineering.
Juvena Therapeutics
Juvena Therapeutics is a computationally-driven biopharmaceutical company focused on discovering and developing novel biologic medicines derived from secreted proteins to restore tissue homeostasis and treat degenerative diseases such as myopathies and metabolic disorders. Utilizing an AI-enabled platform, Juvena mines a diverse library of proteins secreted by human stem cells, mapping their therapeutic potential through in silico, in vitro, and in vivo methods, and engineers these proteins into biologics that promote tissue repair and regeneration. Their lead asset, JUV-161, is in Phase 1 clinical trials for myotonic dystrophy type 1 and sarcopenia, with additional preclinical programs targeting obesity, lung, and liver diseases. Juvena has established significant collaborations, including with the Myotonic Dystrophy Foundation and Eli Lilly, and has been recognized as a World Economic Forum Technology Pioneer and featured in major biotech news outlets. The company operates from Redwood City, California, and is led by a team of experts in computational drug discovery, proteomics, pharmacology, and protein engineering.